![Raymond Sanchez](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Raymond Sanchez
Direktor/Vorstandsmitglied bei
RAPPORT THERAPEUTICS, INC.
Vermögen: - $ am 30.06.2026
Profil
Derzeit ist Raymond Sanchez Chief Medical Officer von Cerevel Therapeutics Holdings, Inc. Außerdem ist er Mitglied des Vorstands der Connecticut Mental Health Center Foundation und Executive Co-Chairman der International Society for CNS Drug Development. In seiner früheren Laufbahn hatte er die Position des Chief Medical Officer bei Avanir Pharmaceuticals, Inc. inne. Raymond Sanchez erwarb einen Bachelor-Abschluss an der Northwestern University und einen Doktortitel an der Feinberg School of Medicine.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 14.04.2026 | 0 ( -.--% ) | - $ | 30.06.2026 |
Aktive Positionen von Raymond Sanchez
| Unternehmen | Position | Beginn |
|---|---|---|
| RAPPORT THERAPEUTICS, INC. | Direktor/Vorstandsmitglied | 07.11.2024 |
| ALTO NEUROSCIENCE, INC. | Direktor/Vorstandsmitglied | 13.08.2025 |
Connecticut Mental Health Center Foundation | Direktor/Vorstandsmitglied | - |
Yale School of Medicine
 Yale School of Medicine Other Consumer ServicesConsumer Services Functions as a College/University | Direktor/Vorstandsmitglied | - |
Bain Capital Life Sciences LP
 Bain Capital Life Sciences LP Investment ManagersFinance Bain Capital Life Sciences invests in public and private companies located across the globe. The firm focuses on biopharmaceutical, specialty pharmaceuticals, medical device, diagnostic and life science technology sectors. It provides financing for buyout and growth stage capital requirements with an investment size of USD 25 - 100 million. | Private Equity Investor | 01.09.2024 |
Ehemalige bekannte Positionen von Raymond Sanchez
| Unternehmen | Position | Ende |
|---|---|---|
| CEREVEL THERAPEUTICS HOLDINGS, INC. | Technik-/Wissenschafts-/F&E-Leiter | 01.08.2024 |
International Society for CNS Drug Development
 International Society for CNS Drug Development Miscellaneous Commercial ServicesCommercial Services The non-profit company is based in San Diego, CA. It promotes collaboration among academia, industry, and government to address scientific challenges in CNS drug development. ISCDD provides resources such as the GRID-Hamilton Depression Rating Scale (GRID-HAMD), which separately rates symptom intensity and frequency, and the Medication Satisfaction Questionnaire (MSQ), both available for licensing and adaptable to various languages and settings. The organization also offers the Uncorrelated PANSS Score Matrix (UPSM™), an analytical tool for refining the assessment of schizophrenia symptoms. The society facilitates knowledge sharing through annual meetings. The International Society for CNS Drug Development (ISCDD) is a non-profit, independent organization founded in 2002 to advance methodologies in central nervous system (CNS) research. | Vorsitzender | 01.01.2022 |
| AVANIR PHARMACEUTICALS INC | Technik-/Wissenschafts-/F&E-Leiter | 01.01.2019 |
Otsuka Pharmaceutical Development & Commercialization, Inc.
 Otsuka Pharmaceutical Development & Commercialization, Inc. Pharmaceuticals: MajorHealth Technology Develops, manufactures and markets pharmaceutical products | Corporate Officer/Principal | 01.01.2019 |
Ausbildung von Raymond Sanchez
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
60
Beziehungen ersten Grades
11
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 11 |
|---|---|
Avanir Pharmaceuticals, Inc.
 Avanir Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops therapeutic products for the treatment of nervous system disorder | Health Technology |
Otsuka Pharmaceutical Development & Commercialization, Inc.
Otsuka Pharmaceutical Development & Commercialization, Inc. Pharmaceuticals: MajorHealth Technology Develops, manufactures and markets pharmaceutical products | Health Technology |
Northwestern University
 Northwestern University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
International Society for CNS Drug Development
International Society for CNS Drug Development Miscellaneous Commercial ServicesCommercial Services The non-profit company is based in San Diego, CA. It promotes collaboration among academia, industry, and government to address scientific challenges in CNS drug development. ISCDD provides resources such as the GRID-Hamilton Depression Rating Scale (GRID-HAMD), which separately rates symptom intensity and frequency, and the Medication Satisfaction Questionnaire (MSQ), both available for licensing and adaptable to various languages and settings. The organization also offers the Uncorrelated PANSS Score Matrix (UPSM™), an analytical tool for refining the assessment of schizophrenia symptoms. The society facilitates knowledge sharing through annual meetings. The International Society for CNS Drug Development (ISCDD) is a non-profit, independent organization founded in 2002 to advance methodologies in central nervous system (CNS) research. | Commercial Services |
Yale School of Medicine
Yale School of Medicine Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Feinberg School of Medicine
 Feinberg School of Medicine Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Bain Capital Life Sciences LP
Bain Capital Life Sciences LP Investment ManagersFinance Bain Capital Life Sciences invests in public and private companies located across the globe. The firm focuses on biopharmaceutical, specialty pharmaceuticals, medical device, diagnostic and life science technology sectors. It provides financing for buyout and growth stage capital requirements with an investment size of USD 25 - 100 million. | Finance |
Cerevel Therapeutics Holdings, Inc.
 Cerevel Therapeutics Holdings, Inc. BiotechnologyHealth Technology Operates as a clinical stage biotechnology company that develops novel therapies for neurological and psychiatric disorders | Health Technology |
Connecticut Mental Health Center Foundation | |
Alto Neuroscience, Inc.
 Alto Neuroscience, Inc. BiotechnologyHealth Technology Engages in psychiatric drug development | Health Technology |
Rapport Therapeutics, Inc.
 Rapport Therapeutics, Inc. BiotechnologyHealth Technology Operates as an clinical-stage biotechnology company that engages in discovery and development of medicines for neurological disorder | Health Technology |
